Document Detail

Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis.
MedLine Citation:
PMID:  10877245     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: A double-blind, single-site, split-face clinical study was organized and carried out in order to evaluate the efficacy, tolerability, and safety of a glycolic acid containing scalp lotion in conjunction with a betamethasone (as the 17-valerate) scalp application against conditions of psoriasis. BACKGROUND: Alpha-hydroxy acids (AHA) have been proposed as therapeutic modalities against skin exfoliative conditions such as ichthyosis, xeroderma, and psoriasis. AHAs are hereby clinically investigated as therapeutic modalities adjuvant to corticosteroids in order to diminish systemic and topical adverse side-effects most frequently associated with use of the latter. METHODS: Twenty patients suffering from scalp psoriasis and other psoriatic conditions were included in a double-blind, split-face clinical study, using combinations of a 10% (w/w) glycolic acid scalp lotion, placebo lotion (excipients only), and a 0.1% (w/w) betamethasone scalp application, applied twice daily without any bandage for a period of 8 weeks. Clinical assessments were carried out by highly experienced physician evaluations based on a four-grade scale, prior to treatment and after 2, 4, 6 and 8 weeks. RESULTS: Improvement was observed in all cases included in the study following treatment with the 10% glycolic acid lotion. However, when equal parts of the 0.1% betamethasone lotion were combined, most of the treated sites were healed. Moreover, the duration of treatment required for healing was in this case reduced to approximately half of that needed when the glycolic acid or the betamethasone lotions were used separately for treatment. CONCLUSIONS: The present clinical study demonstrates for the first time that the effective and well tolerated therapeutic efficacy of glycolic acid scalp lotions is enhanced when used in conjunction with a 0.1% betamethasone scalp application against scalp psoriasis. This potential offers the practising dermatologist with novel treatment modes against severe skin conditions by combining topical corticosteroid with exfoliative agent therapy.
K Kostarelos; A Teknetzis; I Lefaki; D Ioannides; A Minas
Related Documents :
2938615 - Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison wi...
18689735 - Passive treatment of acid mine drainage with high metal concentrations using dispersed ...
6697665 - The importance of conjugation in biliary secretion of ursodeoxycholate and 7-ketolithoc...
16924055 - Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomi...
21870885 - Environmental comparison of bio-based chemicals from glutamic acid with their petrochem...
4363555 - Relationship of cellular fatty acid composition to survival of lactobacillus bulgaricus...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  14     ISSN:  0926-9959     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2000 Jan 
Date Detail:
Created Date:  2000-11-03     Completed Date:  2000-11-03     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  5-9     Citation Subset:  IM    
Research and Development Section, Farmeco Co., Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Anti-Inflammatory Agents / therapeutic use*
Betamethasone 17-Valerate / therapeutic use*
Dosage Forms
Double-Blind Method
Drug Synergism
Glycolates / therapeutic use*
Lactic Acid / therapeutic use*
Pharmaceutical Preparations
Psoriasis / drug therapy*
Scalp Dermatoses / drug therapy*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Dosage Forms; 0/Glucocorticoids; 0/Glycolates; 0/Pharmaceutical Preparations; 2152-44-5/Betamethasone 17-Valerate; 50-21-5/Lactic Acid; 79-14-1/glycolic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vivo spectroscopy in dermatology: methods and new fields of application.
Next Document:  Recidivans cutaneous leishmaniasis unresponsive to liposomal amphotericin B (AmBisome).